Daclatasvir,Sofosbuvir (Co-Administered) Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Daclatasvir 60 mg + Sofosbuvir 400 mg
Reference Brands: Daklinza + Sovaldi(Combo)
Category:
Hepatitis
Daclatasvir and Sofosbuvir tablets are a potent oral antiviral combination for treating chronic Hepatitis C infection. This fixed-dose therapy targets multiple HCV genotypes by inhibiting viral replication enzymes. Manufactured under EU-GMP and USFDA standards, it is widely used in B2B supply, hospital tenders, and global markets with full regulatory support for quick registration.
Daclatasvir,sofosbuvir (co-administered) is available in Tablet
and strengths such as Daclatasvir 60 mg + Sofosbuvir 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Daclatasvir,sofosbuvir (co-administered) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Daclatasvir,sofosbuvir (co-administered) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Daclatasvir and Sofosbuvir Tablets are an oral, fixed-dose combination used to treat chronic Hepatitis C infection across multiple genotypes. Daclatasvir is an NS5A inhibitor, and Sofosbuvir is an NS5B polymerase inhibitor; together, they provide a highly effective, well-tolerated antiviral regimen. Available as 60 mg Daclatasvir and 400 mg Sofosbuvir tablets, manufactured under EU-GMP and USFDA standards. Ideal for B2B licensing, hospital tenders, and global distribution with full CTD dossiers for fast registration in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing